Neratinib +/- Fulvestrant in HER2+, ER+ Metastatic Breast Cancer
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Neratinib|DRUG: Fulvestrant
Sponsor: Dana-Farber Cancer Institute
Collaborators: Puma Biotechnology, Inc.